#watchnow Following the publication of a final LCD and confirmed Medicare coverage for Cxbladder Triage and Triage Plus last week, Pacific Edge CEO Dr Peter Meintjes sat down with Lel Smits from Australian investor platform The Stock Network ahead of the upcoming Bell Potter Healthcare Conference.
In the interview, Dr Meintjes discusses the significance of Medicare coverage, the clinical evidence underpinning our tests, and what the decision means for patients and physicians as Pacific Edge continues to build momentum in the US. He also looks ahead to the development and commercialisation pathway for Surveillance Plus, a next-generation Cxbladder test for patients being monitored for recurrent disease.
Watch the interview below.
Pacific Edge (ASX:PEB) CEO Dr Peter Meintjes is speaking ahead of presenting at Bell Potter’s Healthcare Conference, discussing the company’s newly confirmed US Medicare coverage for its Cxbladder Triage and Triage Plus tests, its growing commercial traction in the US healthcare market and the development of its next bladder cancer test.
TSN Interview:
🇺🇸 Securing US Medicare coverage for bladder cancer testing
🔬 Expanding access to Cxbladder tests across the US healthcare market
🧬 Developing the next generation of bladder cancer testing
⚡ Watch the full interview: www.youtube.com/watch?v=OAzNDlzkGSY&list=PLSnVjgee2Jue6Id…
Register for Bell Potter's Healthcare conference:
🗓 17-19 Nov 2026
👉 bellpotterevent.com.au/healthcare-2026-partner/ @PacificEdgeLtd $PEB @MedicareGov @Bell_Potter
















































































































































































































































































































































































































































































































































